The Wistar Institute
Novel DNA-based Immunotherapy for Neutralizing Hepatitis B Virus infection
PHILADELPHIA — (May. 28, 2020) — Scientists at The Wistar Institute developed a synthetic DNA approach that instructs in vivo production of a human monoclonal antibody able to neutralize hepatitis B virus (HBV) and prevent infection of liver cells i…
Positive Results from Preclinical Testing Support Clinical Development of COVID-19 DNA Vaccine
PHILADELPHIA — (May 20, 2020) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious disease, announces a study reporting initial immunogenicity of a synthetic DNA vaccine for SARS-CoV-2 developed in…
Philanthropy Powering Science: $1.6M in New Funding for Wistar Coronavirus Research
In mere weeks, philanthropic support of Wistar’s Coronavirus Discovery Fund has exceeded $1.6M in new funding thanks to an extraordinary response from individuals, foundations, and corporate sponsors. As our scientists focused their resear…
Spotlight on Wistar COVID-19 Researcher: Hildegund C.J. Ertl, M.D.
Dr. Ertl is a global leader in Wistar’s Vaccine & Immunotherapy Center whose research focuses on preventing rabies, HBV, HIV, HPV, influenza, and other deadly viruses using innovative patented technologies. In response to the global COVID-19 eme…
#Funding4Cure 2020: Supporting Cancer Research Virtually During the Pandemic
The Pennsylvania Cancer Alliance, a coalition of the state’s leading cancer research institutions, meets every year in early May for a lobbying initiative to engage legislators and spotlight the impact the Commonwealth Universal Research Enhancement…
The Wistar Institute Appoints Bin Tian, Ph.D., as Professor in the Cancer Center and Co-director of the Center for Systems & Computational Biology
PHILADELPHIA — (May, 1, 2020) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announces the appointment of molecular systems biologist Bin Tian, Ph.D., as professor in the Cancer Cen…
The Wistar Institute and Batavia Biosciences Launch Collaboration to Manufacture and Distribute Wistar’s Rubella Vaccine Globally
PHILADELPHIA — (April 29, 2020) — The Wistar Institute and Batavia Biosciences announce the launch of a strategic collaboration aimed to streamline the clinical grade manufacture and global distribution of Wistar’s rubella vaccine seed stock commonl…
Uncertain Times: Wistar’s Historic Strides in the Time of COVID-19
This is week six of the stay-at-home order in Pennsylvania and Darien Sutton, associate director of Communications & Marketing, caught up again with President and CEO Dario C. Altieri, M.D., for their second virtual chat about what’s going on wi…
Spotlight on Wistar COVID-19 Researchers: Luis Montaner, D.V.M., D.Phil., & Joseph Salvino, Ph.D.
Dr. Luis Montaner is an HIV expert focused on finding new ways to boost the natural function of the immune system to combat infection or viral-associated disease. Dr. Joseph Salvino is a medicinal chemist and an expert in drug discovery and identifi…
Spotlight on Wistar COVID-19 Researcher: Daniel Kulp, Ph.D., Associate Professor
Principal investigator Dr. Daniel Kulp is one of a group of Wistar scientists undertaking coronavirus research in response to the pandemic. A protein engineering expert, his lab focuses on rational vaccine and therapeutic antibody design for a varie…